Replimune Group (NASDAQ:REPL) Trading Up 6.1%

Replimune Group, Inc. (NASDAQ:REPL)’s stock price was up 6.1% during mid-day trading on Tuesday . The stock traded as high as $11.64 and last traded at $11.63. Approximately 451,730 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 1,116,355 shares. The stock had previously closed at $10.96.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on REPL shares. JPMorgan Chase & Co. raised their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm initiated coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Monday, September 16th. Barclays increased their target price on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $16.80.

Replimune Group Trading Up 8.6 %

The company has a 50 day moving average of $10.36 and a 200 day moving average of $8.52. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market cap of $813.01 million, a price-to-earnings ratio of -3.33 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.10. As a group, research analysts anticipate that Replimune Group, Inc. will post -3.11 EPS for the current year.

Insider Activity at Replimune Group

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now directly owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quest Partners LLC increased its stake in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after buying an additional 3,150 shares during the period. Algert Global LLC increased its stake in shares of Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after buying an additional 4,340 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Replimune Group by 72.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after buying an additional 4,975 shares during the period. Finally, Los Angeles Capital Management LLC increased its stake in shares of Replimune Group by 8.1% in the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after buying an additional 5,410 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.